A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsTools Elborn, J. Stuart, Geller, David E., Conrad, Douglas, Aaron, Shawn D., Smyth, Alan R., Fischer, Rainald, Kerem, Eitan, Bell, Scott C., Loutit, Jeffery S., Dudley, Michael N., Morgan, Elizabeth E., VanDevanter, Donald R. and Flume, Patrick (2015) A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 14 (4). pp. 507-514. ISSN 1873-5010 Full text not available from this repository.AbstractBackground: Inhaled antibiotics are standard of care for persons with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa airway infection. APT-1026 (levofloxacin inhalation solution, LIS) is fluoroquinolone in development. We compared the safety and efficacy of LIS to tobramycin inhalation solution (TIS) in persons ≥12 years old with CF and chronic P. aeruginosa infection.
Actions (Archive Staff Only)
|